A method of treating a synucleinopathy with a peptide

TABLE-US-00001 (C)DQPVLPD (SEQ ID NO: 59), (C)DMPVLPD (SEQ ID NO: 60), (C)DSPVLPD (SEQ ID NO: 61), (C)DQPVLPDN (SEQ ID NO: 64), (C)DMPVLPDN (SEQ ID NO: 65), (C)DSPVLPDN (SEQ ID NO: 66), (C)HDRPVTPD (SEQ ID NO: 70), (C)DRPVTPD (SEQ ID NO: 71), (C)DVPVLPD (SEQ ID NO: 72), (C)DTPVYPD (SEQ ID NO: 73), (C)DTPVIPD (SEQ ID NO: 74), (C)HDRPVTPDN (SEQ ID NO: 75), (C)DRPVTPDN (SEQ ID NO: 76), (C)DVPVLPDN (SEQ ID NO: 78), (C)DTPVYPDN (SEQ ID NO: 79), (C)DQPVLPDG (SEQ ID NO: 81), (C)DMPVLPDG (SEQ ID NO: 82), (C)DSPVLPDG (SEQ ID NO: 83), (C)DHPVHPDS (SEQ ID NO: 86), (C)DMPVSPDR (SEQ ID NO: 87), (C)DRPVYPDI (SEQ ID NO: 90), (C)DHPVTPDR (SEQ ID NO: 91), (C)DTPVLPDS (SEQ ID NO: 93), (C)DMPVTPDT (SEQ ID NO: 94), (C)DAPVTPDT (SEQ ID NO: 95), (C)DSPWPDN (SEQ ID NO: 96), (C)DLPVTPDR (SEQ ID NO: 97), (C)DSPVHPDT (SEQ ID NO: 98), (C)DAPVRPDS (SEQ ID NO: 99), (C)DMPVWPDG (SEQ ID NO: 100), (C)DRPVQPDR (SEQ ID NO: 102), (C)YDRPVQPDR (SEQ ID NO: 103), (C)DMPVDADN (SEQ ID NO: 105), DQPVLPD(C) (SEQ ID NO: 106), and DMPVLPD(C) (SEQ ID NO: 107.

The present invention provides pneumococcal conjugate vaccine formulations comprising surfactant systems incorporating polysorbate 20 or a combination of a poloxamer and a polyol.

The invention provides an immunogenic composition comprising OMVs and (a) acellular pertussis antigen, (b) a tetanus toxoid and (c) a diphtheria toxoid, wherein the OMVs are derived from Bordetella pertussis. The invention also provides compositions for use in a method for raising an immune response in a patient, comprising the step of administering to the patient a composition of the invention.

Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Merkel Cell Polyomavirus (MCV) T antigen. Immunomodulatory methods and methods of inducing an immune response against MCV are disclosed. Method of treating infection by MCV and methods of treating or preventing Merkel Cell Carcinoma associated with MCV are disclosed. Modified consensus MCV T antigens are disclosed.

Disclosed are influenza virus-like particles (VLPs), wherein the VLPs include hemagglutinin (HA) protein and neuraminidase (NA) protein on the surface of the VLPs, a nucleoprotein (NP) ribonucleoprotein complex, and wherein the VLPs do not contain a ribonucleoprotein complex of at least one of PB1, PB2, and NS.

There is disclosed a peptide capable of inducing an immune response against: a ASTE1-1a frameshift mutant protein, wherein the peptide comprises at least 10 consecutive amino acids of SEQ ID NO: 26; a TAE1β-1a frameshift mutant protein, wherein the peptide comprises at least 10 consecutive amino acids of SEQ ID NO: 27; a KIAA2018-1a frameshift mutant protein, wherein the peptide comprises a immunogenic fragment of one of SEQ ID NOs: 9-12, wherein the fragment comprises at least 8 consecutive amino acids of one of one of SEQ ID NOs: 9-12; or a SLC22A9-1a frameshift mutant protein, wherein the peptide comprises at least 8 consecutive amino acids of one of SEQ ID NOs: 14-18. There is also disclosed a peptide mixture comprising a first and second peptide, each independently selected from one of the peptides described above and a peptide capable of inducing an immune response against a TΘEβE2-1a frameshift mutant protein.

The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.

Provided is a polynucleotide encoding a respiratory syncytial virus (RSV) variant having an attenuated phenotype comprising a modified RSV genome or antigenome that encodes a mutant RSV protein P that differs from a parental RSV protein P at one or more amino acid residues. In some embodiments, the polynucleotide is recombinant. The invention also relates to methods of vaccinating an animal with the RSV variant or a pharmaceutical composition containing the RSV variant or inducing an immune response by administering the RSV variant to an animal, and further relates to methods of producing an RSV variant vaccine. In some embodiments, the animal is a human.

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PEDIARIX® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine), HAVRIX® (Hepatitis A Vaccine), ENGERIX-B® (Hepatitis B Vaccine (Recombinant)), TWINRIX® (Hepatitis A & Hepatitis B (Recombinant) Vaccine), EPERZAN® (albiglutide), MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (astuprotimut-R), GSK2402968 (drisapersen), and HZ/su (herpes zoster vaccine).

Disclosed are an attenuated live vaccine against mycoplasmal pneumonia of swine (MPS) and use thereof. In the present invention, pathological lung tissues of swine having typical Mycoplasma hyopneumoniae (Mhp) infection and no obvious other pathogenic infections are screened, and subcultured 100 generations in lungs of newborn rabbits; then, Mhp strains are isolated and serially subcultured in a medium; and the Mhp strain AN306 is obtained by screening a plurality of strains, which is deposited with an accession number: CCTCC NO. M2012431. Also disclosed is a live vaccine formulation against MPS prepared on the basis of the attenuated strain and comprising live attenuated strain, a pharmaceutically acceptable carrier or excipient, and optionally an adjuvant and immunogens of other pathogens.